CHLOROTHIAZIDE AND RESERPINE
Clinical safety rating: safe
MAOIs can cause excitability and hypertension Can cause depression and suicidal ideation.
Chlorothiazide is a thiazide diuretic that inhibits the sodium-chloride symporter in the distal convoluted tubule, reducing sodium and chloride reabsorption, leading to increased diuresis and vasodilation. Reserpine is an adrenergic neuron blocking agent that depletes catecholamines and serotonin from central and peripheral nerve endings, reducing sympathetic outflow and lowering blood pressure.
| Metabolism | Chlorothiazide is not metabolized and is excreted unchanged by the kidneys. Reserpine is extensively metabolized in the liver via hydrolysis and glucuronidation, with metabolites excreted in urine and feces. |
| Excretion | Chlorothiazide: Primarily renal excretion via tubular secretion (90-95% unchanged); Reserpine: Fecal (60-70%) and renal (30-40%) excretion as metabolites. |
| Half-life | Chlorothiazide: 45-120 minutes (short, requires multiple daily doses); Reserpine: 50-100 hours (biphasic, prolonged effect due to irreversible adrenergic neuron blockade). |
| Protein binding | Chlorothiazide: 40-60% (primarily albumin); Reserpine: 95-98% (mainly alpha-1-acid glycoprotein and albumin). |
| Volume of Distribution | Chlorothiazide: 0.5-1.0 L/kg (limited to extracellular fluid); Reserpine: 8-10 L/kg (extensive, accumulates in adipose and neuronal tissue). |
| Bioavailability | Chlorothiazide: Oral 30-50% (variable due to saturable absorption); Reserpine: Oral 40-50% (significant first-pass metabolism). |
| Onset of Action | Chlorothiazide: Oral 2-3 hours; Reserpine: Oral 3-6 days (gradual onset due to slow depletion of catecholamines). |
| Duration of Action | Chlorothiazide: 6-12 hours; Reserpine: 4-6 weeks (prolonged, persists until catecholamine repletion). |
Oral: 250-500 mg chlorothiazide (component) plus 0.125-0.25 mg reserpine once or twice daily. Maximum chlorothiazide dose: 1000 mg/day.
| Dosage form | TABLET |
| Renal impairment | Contraindicated if CrCl <30 mL/min. For CrCl 30-50 mL/min: reduce chlorothiazide dose by 50% or increase interval to every 48 hours. Reserpine is poorly dialyzable; avoid in severe renal impairment. |
| Liver impairment | Child-Pugh A: no adjustment. Child-Pugh B: consider reducing reserpine dose by 50% due to increased risk of CNS depression. Child-Pugh C: avoid use due to risk of hepatic encephalopathy. |
| Pediatric use | Chlorothiazide: 10-20 mg/kg/day orally in 2 divided doses (max 375 mg/day for children <2 years, 1000 mg/day for older children). Reserpine: 0.02 mg/kg/day orally in 1-2 doses (max 0.25 mg/day). |
| Geriatric use | Start at lowest dose: chlorothiazide 250 mg plus reserpine 0.125 mg once daily. Titrate slowly due to increased sensitivity to hypotension, electrolyte imbalances, and CNS effects. Avoid in patients with a history of depression. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
MAOIs can cause excitability and hypertension Can cause depression and suicidal ideation.
| FDA category | Animal |
| Breastfeeding | Chlorothiazide excreted in breast milk in low amounts; reserpine excreted in breast milk with M/P ratio not established. Potential for adverse effects in infant (e.g., electrolyte disturbances, bradycardia). Use caution; consider alternative agents. |
| Teratogenic Risk | First trimester: Limited data; chlorothiazide crosses placenta and may cause electrolyte disturbances; reserpine associated with increased risk of congenital malformations (neural tube defects, cardiovascular) in animal studies. Second/third trimester: Chlorothiazide may cause fetal or neonatal jaundice, thrombocytopenia, and electrolyte imbalances; reserpine may cause neonatal respiratory depression, bradycardia, and nasal congestion. Use only if benefit outweighs risk. |
■ FDA Black Box Warning
Reserpine may cause mental depression, and the drug should be discontinued at the first sign of depression. Electroshock therapy may increase the risk of severe reactions; reserpine should be discontinued at least one week before electroshock therapy is initiated.
| Common Effects | Depression |
| Serious Effects |
Hypersensitivity to chlorothiazide, reserpine, or sulfonamide-derived drugs; anuria; history of depression, especially with suicidal tendencies; active peptic ulcer; ulcerative colitis; patients receiving electroshock therapy.
| Precautions | May cause hypotension, bradycardia, drowsiness, depression, and gastrointestinal distress. Use with caution in patients with history of peptic ulcer, ulcerative colitis, or gallstones (reserpine). Monitor electrolytes and renal function (chlorothiazide). May exacerbate systemic lupus erythematosus. Avoid abrupt withdrawal. |
Loading safety data…
| Fetal Monitoring | Monitor maternal blood pressure, serum electrolytes, renal function, and fetal growth (ultrasound). Assess for neonatal adverse effects at delivery: jaundice, thrombocytopenia, bradycardia, respiratory depression. |
| Fertility Effects | Reserpine may impair fertility due to its catecholamine-depleting effects, potentially causing anovulation or menstrual irregularities. Chlorothiazide may affect electrolyte balance but no direct fertility impact reported. |
| Food/Dietary |
| Avoid excessive salt intake to prevent fluid retention. Limit alcohol consumption. May require potassium-rich foods (e.g., bananas, oranges) if hypokalemia develops; avoid excessive potassium supplements unless advised. |
| Clinical Pearls | Chlorothiazide is a thiazide diuretic; reserpine is a Rauwolfia alkaloid that depletes catecholamines. Monitor for hypokalemia, hyperuricemia, and orthostatic hypotension. Avoid in patients with history of depression, peptic ulcer, or elective surgery due to reserpine's CNS effects. Combination may be used for hypertension refractory to monotherapy. |
| Patient Advice | Take with food or milk to reduce stomach upset. · Avoid sudden standing to prevent dizziness; rise slowly. · May cause drowsiness; avoid driving until effects known. · Report slow heartbeat, fainting, or mood changes. · Limit alcohol intake as it may worsen dizziness. |